Intravenous immunoglobulin therapy for neuromuscular disorders.

Intravenous immunoglobulin therapy for neuromuscular disorders. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Intravenous immunoglobulin therapy for neuromuscular disorders. Abstract Text:

Mark A Ross,

Treatment of specific immune-mediated neuromuscular disorders involves consideration of many factors including severity of illness, concurrent medical problems, supportive therapies, and immune-modulating therapies. Many immune-modulating therapies are available, including steroids, an increasing number of immunosuppressive drugs, plasmapheresis, and intravenous immunoglobulin (IVIG). Deciding on which immune-modulating therapy involves selecting from those with proven efficacy for a specific disorder and global considerations of which therapies are most appropriate for an individual patient's circumstances. IVIG has become a commonly used therapy as it is well tolerated, easily administered, and is often efficacious with a relatively rapid action. IVIG has become a first-line therapy for several immune-mediated demyelinating polyneuropathies and may play a role in treating exacerbations of myasthenia gravis and selected chronic treatment-refractory cases of Lambert-Eaton myasthenic syndrome, dermatomyositis, and polymyositis.

Intravenous immunoglobulin therapy for neuromuscular disorders. Publishing Authors By Initials

MA Ross,

For similar nervous system diseases: neuromuscular diseases research abstracts see: nervous system diseases: neuromuscular diseases research

PUBMED ID PMID:

MEDLINE DATE:

Intravenous immunoglobulin therapy for neuromuscular disorders. Journal Published:

PUBLICATION TYPE: Review

Journal: Seminars in neurology

VOLUME: 27

Page Numbers: 340-6

Journal Abbreviation:

ISSN: 0271-8235

DAY: 28

MONTH: Sep

YEAR: 2007

Intravenous immunoglobulin therapy for neuromuscular disorders. Information

Number of References: 49

LANGUAGE: eng

NlmUniqueID: 8111343

Intravenous immunoglobulin therapy for neuromuscular disorders. Keywords Mesh Terms:

KEYWORDS: Neuromuscular Diseases

MESH TERMS: therapy

Chemical & Substance for Abstract: Intravenous immunoglobulin therapy for neuromuscular disorders. Information

Substance Name: Immunologic Factors

Registry Number: 0

Grant and Affiliation Information for Intravenous immunoglobulin therapy for neuromuscular disorders.

AFFILIATION: Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona 85259, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Semin Neurol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Intravenous immunoglobulin therapy for neuromuscular disorders Related Publications

• A minimum CR2 binding domain of C3d enhances immunity following vaccination.
• Attitudes of genetic counselors towards expanding newborn screening and offering predictive genetic testing to children.
• Benjamin M. Baker, JR.: 1901-2003.
• Birth characteristics, maternal reproductive history, and the risk of infant leukemia: a report from the Children's Oncology Group.
• Carnitine as a possible adjunct in parenteral feeding.
• Chronic vitamin A status and acute repletion with retinyl palmitate are determinants of the distribution and catabolism of all-trans-retinoic acid in rats.
• Circadian rhythms play role in cancer research.
• Complement inactivating proteins and intraspecies venom variation in Crotalus oreganus helleri.
• Differences in cyclin D2 and D1 protein expression distinguish forebrain progenitor subsets.
• Diffusion imaging: insight to cell status and cytoarchitecture.
• Failure of embryos from bluetongue infected cattle to transmit virus to susceptible recipients or their offspring.
• Gestational programming of offspring obesity/hypertension.
• Kinetics of glial glutamine efflux and the mechanism of neuronal uptake studied in vivo in mildly hyperammonemic rat brain.
• Language use in females with fragile X or Turner syndrome during brief initial social interactions.
• Lentivirus-like particles without reverse transcriptase elicit efficient immune responses.
• Maternal hemoglobin concentration during pregnancy and risk of infant leukaemia: a children's oncology group study.
• More to the E-Ferol case than presented.
• Neurologic Manifestations
  of HIV Infection Without AIDS:Follow-UP of a Cohort
  of Homosexual and Bisexual Men.
• Penicillin; applied pharmacology.
• Phosphorylation-regulated inhibition of the Gz GTPase-activating protein activity of RGS proteins by synapsin I.
• Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy.
• Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance.
• Random activation energy model and disordered kinetics, from static to dynamic disorder.
• Reduction of anti-HIV-1 Gag immune responses during co-immunization: immune interference by the HIV-1 envelope.
• Species differences in the in vitro metabolism of deltamethrin and esfenvalerate: differential oxidative and hydrolytic metabolism by humans and rats.
• The effect of lactation length on the circulating concentrations of progesterone and oestradiol in the early weaned sow.
• Transoral surgery: an anatomic study.
• Use of modified pericranial flaps in anterior skull base reconstruction: technical note.
• Vascular targeted nanoparticles for imaging and treatment of brain tumors.
• Virus-like particles: designing an effective AIDS vaccine.